US · COEP
Coeptis Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Wexford, PA 15090
- Website
- coeptispharma.com
Price · as of 2024-12-31
—
Market cap 42.29M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $198.00 | ||||
| 2021 | $201.10 | $164.26 | $0.00 | $0.00 | $0.00 |
| 2022 | $26.60 | $44.93 | |||
| 2023 | $9.60 | ||||
| 2024 | $10.59 |
AI valuation
Our deep-learning model estimates Coeptis Therapeutics, Inc.'s (COEP) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| COEP | Coeptis Therapeutics, Inc… | $12.04 | 42.29M | — | — | — | — | -1.87 | 6.40 | — | -2.25 | -0.32 | 7.72 | 0.00% | — | — | -290.10% | -247.64% | -128.12% | 0.44 | -25.38 | 0.23 | 0.12 | -0.09 | 58072.00% | — | -815.00% | -32.60% | -1.47 | -163.77% | 0.00% | 0.00% | 0.00% | -2.11 | -3.20 | — | -17.20 |
| CUE | Cue Biopharma, Inc. | $0.28 | 22.08M | +11,310% | +57% | — | — | -1.52 | 3.54 | 6.67 | -1.26 | — | 3.54 | 100.00% | -446.86% | -437.97% | -149.03% | -1327.36% | -86.80% | 0.51 | -52.14 | 1.84 | 1.78 | 0.36 | -3514.00% | 6916.00% | -892.00% | -58.74% | -2.65 | -1164.08% | 0.00% | 0.00% | 0.00% | -1.14 | -1.30 | 5.11 | -15.88 |
| EQ | Equillium, Inc. | $1.82 | 64.65M | +1,406% | -79% | — | — | -3.51 | 1.48 | 0.69 | -0.81 | — | 1.48 | 100.00% | -20.12% | -19.63% | -38.75% | 80.29% | -21.19% | 0.02 | — | 3.93 | 3.73 | 2.34 | -3947.00% | 1389.00% | -1247.00% | -67.56% | -2.99 | 185.55% | 0.00% | 0.00% | 0.00% | -0.74 | -0.32 | 0.15 | -6.59 |
| IPSC | Century Therapeutics, Inc… | $2.32 | 202.78M | +1,581% | -88% | — | — | -0.41 | 0.32 | 7.82 | 0.75 | — | 0.41 | 100.00% | -2096.48% | -1920.87% | -73.14% | -320.94% | -35.46% | 0.33 | — | 1.50 | 1.47 | 0.04 | -3000.00% | 19481.00% | 804.00% | -214.09% | -0.85 | -256.24% | 0.00% | 0.00% | 10.59% | 0.61 | 0.76 | -12.74 | -3.99 |
| KPTI | Karyopharm Therapeutics I… | $9.41 | 80.34M | +75% | -59% | — | — | -0.53 | -0.36 | 0.72 | -3.04 | -0.59 | -0.36 | 95.93% | -62.10% | -134.21% | 81.86% | 81.25% | -143.71% | -0.80 | -1.98 | 1.12 | 0.98 | -1.91 | 9054.00% | 57.00% | -4095.00% | -71.87% | -0.82 | 67.51% | 0.00% | 0.00% | 0.00% | -3.03 | -3.65 | 1.88 | -23.86 |
| MDCX | Medicus Pharma Ltd. Commo… | $1.53 | 37.8M | — | — | — | — | -2.63 | 9.36 | — | -2.29 | — | 9.36 | 0.00% | — | — | -525.44% | 1700.21% | -295.90% | 0.10 | -35.21 | 2.33 | 1.81 | 0.34 | -2810.00% | — | 14643.00% | -34.93% | -4.44 | 1558.23% | 0.00% | 0.00% | 7.24% | -2.28 | -2.49 | — | -6.04 |
| NRXP | NRx Pharmaceuticals, Inc. | $1.86 | 32.15M | — | — | — | — | -0.91 | -0.98 | — | -1.16 | — | -0.98 | 0.00% | — | — | 143.76% | 156.03% | -458.25% | -0.28 | -18.26 | 0.15 | 0.07 | -0.21 | -3995.00% | — | -5089.00% | -46.61% | -0.49 | 84.23% | 0.00% | 0.00% | 0.00% | -1.42 | -2.63 | — | -130.11 |
| OTLK | Outlook Therapeutics, Inc… | $0.42 | 17.31M | — | +90,898,778% | — | — | 0.00 | 0.00 | 50.46 | 123242.30 | — | 0.00 | 46.49% | -4744.25% | -4416.22% | 387.88% | 0.00% | -671.81% | -0.01 | -236.86 | 0.38 | 0.18 | 123243.42 | -5591.00% | — | 7534010988.00% | -72659652.79% | -1.13 | 259.00% | 0.00% | 0.00% | 10984444.51% | 116837.47 | 0.15 | -5543064.49 | -47.47 |
| SNTI | Senti Biosciences, Inc. | $0.94 | 24.82M | +2,578% | — | — | — | -0.31 | 0.63 | — | -0.03 | — | 0.63 | 0.00% | — | — | -114.06% | -153.24% | -48.58% | 1.31 | — | 4.49 | 3.81 | 0.27 | -4513.00% | -10000.00% | -3571.00% | -256.05% | -3.15 | -103.99% | 0.00% | 0.00% | 101.22% | -0.03 | -0.04 | — | -5.61 |
| TELO | Telomir Pharmaceuticals, … | $1.27 | 43.66M | — | — | — | — | -7.77 | 199.83 | — | 2652.56 | -28.50 | 199.83 | 0.00% | — | — | -810.18% | -813.89% | -542.25% | 0.15 | 2.82 | 1.94 | 1.86 | -24.43 | 2727.00% | — | 3137.00% | -3.95% | -7.45 | -337.09% | 0.00% | 0.00% | 0.99% | -10.40 | -25.11 | — | 50.93 |
About Coeptis Therapeutics, Inc.
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
- CEO
- David Mehalick
- Employees
- 5
- Beta
- -0.50
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).